Stock Scorecard
Stock Summary for Madrigal Pharmaceuticals Inc (MDGL) - $396.32 as of 11/3/2026 8:25:02 PM EST
Total Score
7 out of 30
Safety Score
54 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MDGL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MDGL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MDGL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MDGL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for MDGL (54 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for MDGL
Financial Details for MDGL
Company Overview |
|
|---|---|
| Ticker | MDGL |
| Company Name | Madrigal Pharmaceuticals Inc |
| Country | USA |
| Description | Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | 11/3/2026 |
Stock Price History |
|
| Last Day Price | 396.32 |
| Price 4 Years Ago | 290.25 |
| Last Day Price Updated | 11/3/2026 8:25:02 PM EST |
| Last Day Volume | 1,978,574 |
| Average Daily Volume | 292,589 |
| 52-Week High | 615.00 |
| 52-Week Low | 399.00 |
| Last Price to 52 Week Low | 0.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 25.70 |
| Sector PE | 35.68 |
| 5-Year Average PE | -47.52 |
| Free Cash Flow Ratio | 31.28 |
| Industry Free Cash Flow Ratio | 33.94 |
| Sector Free Cash Flow Ratio | 38.34 |
| Current Ratio Most Recent Quarter | 3.20 |
| Total Cash Per Share | 12.67 |
| Book Value Per Share Most Recent Quarter | 22.68 |
| Price to Book Ratio | 19.43 |
| Industry Price to Book Ratio | 7.66 |
| Sector Price to Book Ratio | 32.96 |
| Price to Sales Ratio Twelve Trailing Months | 7.76 |
| Industry Price to Sales Ratio Twelve Trailing Months | 29.18 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.60 |
| Analyst Buy Ratings | 15 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 23,104,100 |
| Market Capitalization | 9,156,616,912 |
| Institutional Ownership | 104.44% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 10.80% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 38.12% |
| Reported EPS 12 Trailing Months | -12.85 |
| Reported EPS Past Year | -3.37 |
| Reported EPS Prior Year | -12.75 |
| Net Income Twelve Trailing Months | -325,095,000 |
| Net Income Past Year | -288,284,000 |
| Net Income Prior Year | -465,892,000 |
| Quarterly Revenue Growth YOY | 71.20% |
| 5-Year Revenue Growth | 747.94% |
| Operating Margin Twelve Trailing Months | -15.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 292,726,000 |
| Total Cash Past Year | 198,693,000 |
| Total Cash Prior Year | 100,019,000 |
| Net Cash Position Most Recent Quarter | -48,068,000 |
| Net Cash Position Past Year | -141,188,000 |
| Long Term Debt Past Year | 339,881,000 |
| Long Term Debt Prior Year | 117,569,000 |
| Total Debt Most Recent Quarter | 340,794,000 |
| Equity to Debt Ratio Past Year | 0.64 |
| Equity to Debt Ratio Most Recent Quarter | 0.61 |
| Total Stockholder Equity Past Year | 602,689,000 |
| Total Stockholder Equity Prior Year | 754,383,000 |
| Total Stockholder Equity Most Recent Quarter | 523,724,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -207,065,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -8.96 |
| Free Cash Flow Past Year | -190,020,000 |
| Free Cash Flow Prior Year | -457,034,000 |
Options |
|
| Put/Call Ratio | 3.06 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -18.05 |
| MACD Signal | -18.59 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | -1.05 |
| RSI | 0.00 |
| 50-Day SMA | 508.51 |
| 150-Day SMA | 368.19 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/30/2026 4:08:57 AM EST |